Tesofensine is an appetite suppressant from the phenyltropane family of drugs, which is being tested for the treatment of obesity. It is developed and marketed by NeuroSearch, a Danish pharmaceutical company. Tesofensine is currently in phase II trials for the treatment of obesity and preparation for phase III trials is also complete. When approved, Tesofensine will be readily available to treat weight loss and counter the effects of obesity.
Tesofensine is a pharmaceutical drug that was originally researched for the treatment of Alzheimer's disease and Parkinson's Disease. It was dropped after early trial results showed limited efficacy for the treatment of Parkinson's disease but showed significant weight loss in users who were obese. Results suggest that Tesofensine may be even more effective than slimming medications currently on the market, such as Xenical and Reductil. Trials in Denmark showed that users who were dieting and taking the highest dose of Tesofensine for 24 weeks lost up to 12.6% of their body weight, double the amount the best current drug treatments can offer.
Tesofensine uses a triple action motion to increase the neurotransmission of 3 monoaminergic neurotransmitters in your brain: dopamine, noradrenaline and serotonin simultaneously. Each of these transmitters plays an important part of suppressing your appetite and controlling your metabolism at different locations in your brain. Dopamine targets your brain's nucleus accumbens to evoke a feeling of fullness that is gained through eating. The 2 other transmitters act in the hypothalamus to increase your metabolism while reducing your hunger levels.
Men who have any of the following conditions should also avoid taking Tesofensine:
If you are unsure whether you are suitable to take obesity drug treatments such as Tesofensine, please consult your doctor or a physician. They can assess your suitability and provide you with relevant information on how to treat your obesity problem.
The side effects of Tesofensine are similar to other currently approved diet pills and weight loss medications. In recent trials, side effects such as dry mouth, insomnia, tachycardia, constipation, nausea, diarrhoea, high blood pressure and increases in heart rate were recorded. However, there were significant improvements in the overall weight-related quality of users as well as their physical functions and increased levels of self-esteem. The 0.5 mg dose of Tesofensine has been adopted as the dose to be tested in phase lll trials as it produced weight loss that was not statistically significantly different from the 1 mg dose, but it showed less effect on blood pressure level of users.
Phase II trials for the treatment of obesity have been completed and preparation for phase III trials is finished. The final stage which began in 2009 is currently in effect. When Tesofensine is approved as an obesity treatment the 0.5 mg dose will be available for you to buy online with a prescription.